TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Instil Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$5.79−0.12 (-2.03%)

Close on Oct 19, 2026

Market cap: $39.27M
P/E (TTM): –
Dividend yield: –

Instil Bio, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	6.64	11	11	44	38	242	8.90
Short-Term Investments	–	–	141	217	417	0	–
Cash & Short-Term Investments	6.64	11	152	261	455	242	8.90
Prepaid Expenses & Other	3.04	9.33	8.90	8.46	9.92	4.42	–
Other Current Assets	0.15	0.96	2.60	–	–	0.07	–
Total Current Assets	191	124	161	269	464	246	–
Property, Plant & Equipment	0.13	129	139	197	122	55	–
Gross Property, Plant & Equipment	0.51	134	146	205	125	56	–
Accumulated Depreciation	-0.38	-4.78	-7.56	-8.48	-2.98	-0.31	–
Construction in Progress	–	–	–	104	67	6.30	–
Long-Term Investments	–	0	23	0	–	–	–
Operating Lease Right-of-Use Assets	0.24	0.93	2.39	12	0	–	–
Goodwill	–	–	–	0	5.72	5.72	–
Other Long-Term Assets	4.07	4.49	0.64	3.41	8.14	1.71	–
Total Assets	204	264	326	482	610	319	–
Accounts Payable	0.78	0.66	1.21	2.36	5.57	3.50	–
Current Portion of Leases	0.37	1.68	1.75	2.38	0	–	–
Other Current Liabilities	–	0	0.19	0.59	0.39	0.28	–
Total Current Liabilities	4.84	7.90	11	33	41	13	–
Long-Term Leases	0	1.02	2.88	5.17	0	–	–
Operating Lease Liabilities	0.37	2.70	4.63	7.55	0	–	–
Deferred Tax Liabilities	–	–	–	0	2.43	2.47	–
Other Long-Term Liabilities	0.01	0.08	0.08	0.33	0.02	0	–
Total Liabilities	90	94	100	119	55	27	–
Preferred Stock	0	0	0	0	0	–	–
Common Stock	0	0	0	0	0	0	–
Additional Paid-In Capital	841	825	807	789	757	5.61	–
Retained Earnings	-726	-655	-581	-425	-202	-45	–
Comprehensive Income & Other	-0.58	-0.23	-0.35	-0.49	-0.09	-0.28	–
Shareholders' Equity	114	169	226	364	555	-40	-6.89
Total Equity	114	169	226	364	555	-40	-6.89
Total Liabilities & Equity	204	264	326	482	610	319	–
Shares Outstanding(shares)	6.78	6.53	6.50	6.50	6.45	1.03	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -50.4%

Financial strength

Current ratio: 21.67
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 167.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.37
Dividend yield: –